BREAKING: Johnson & Johnson Signs On to Lead Delix’s $85M Series C

NEW BRUNSWICK – Johnson & Johnson has agreed to lead a Series C financing for Delix Therapeutics, the biotech developing non-hallucinogenic drugs designed to promote neuroplasticity in patients with serious psychiatric conditions. The round is sized at $85 million at a pre-money valuation of $190 million. The financing has not yet closed.

The structural terms may matter more than the headline number. Embedded in J&J’s term sheet is a right of first negotiation following Phase II data from DLX-001 (Zalsupindole), Delix’s lead compound, covering both the asset and the company as a whole. That clause positions J&J not merely as a capital source, but as first in line should the Phase II readout prompt a more significant conversation.

Delix holds a specific place in the history of psychedelic-derived drug development. Founded in 2019, the company was the first well-capitalized developer to build around non-hallucinogenic neuroplastogens – compounds designed to preserve the neuroplasticity-promoting mechanisms of psychedelics while shedding their hallucinogenic and dissociative properties. It raised more than $100 million in 2021 through rounds led by ARTIS Ventures and RA Capital Management, establishing the category as a legitimate biotech investment thesis.

The clinical foundation for this round rests on data announced in October 2025. Delix’s study of DLX-001 in adults with major depressive disorder (MDD) delivered rapid and durable reductions in depressive symptoms across two dosing regimens, with effects sustained through Day 36. The FDA also cleared a Phase II design allowing patients to self-administer the compound at home, through once-daily or twice-weekly dosing.

That backdrop makes J&J’s entrance particularly meaningful. The pharmaceutical company brings singular experience in psychedelic-adjacent medicine through Spravato (Esketamine), its FDA-approved nasal spray for treatment-resistant depression (TRD) – the closest commercial parallel to the psychedelic therapy model. Delix’s at-home dosing design is precisely the kind of scalable, outpatient framework Spravato could not offer, a differentiation J&J apparently finds worth backing.

The broader competitive context adds texture. AbbVie’s acquisition of Gilgamesh’s bretisilocin for up to $1.2 billion, after earlier engagement with non-hallucinogenic candidates, demonstrated how quickly large pharma commitments in this space can deepen once clinical confidence builds.

The right of first negotiation in J&J’s term sheet is the element most worth watching. It converts a financial investment into a structured option on both DLX-001 and the company itself, timed to Phase II data that will either validate or deflate the non-hallucinogenic neuroplastogen thesis. For Delix, the round resolves a near-term capital problem and restores operational footing after a difficult stretch. For the neuroplastogen sector, J&J’s entry supplies the institutional credibility the category has needed as conventional psychedelics have drawn increasingly competitive investor attention.